For 5’000 CHF the following tests can be financed:
5 FDG PET or
2 tau PET or
2 amyloid PET or
The test measures the regional consumption of glucose in the brain. Glucose is used by neurons to function and communicate and for this reason glucose consumption is an accurate measure of brain “health”. Disease conditions, and in particular neurodegeneration in patients with cognitive problems, are associated with visible changes on FDG PET images. The added value of this test has been largely demonstrated in multiple studies.
The test shows the presence of tau accumulation in the brain. Different forms of tau aggregates exist in neurodegenerative diseases, and this test is particularly designed to show the tau deposits that occur in Alzheimer’s Disease. These tracers have been developed only recently and multiple studies are ongoing to evaluate their precision and added value in patients.
The test shows the presence of amyloid deposits in the brain. The presence of amyloid is one of the elements defining Alzheimer’s Disease. Multiple studies have shown that amyloid PET accurately shows these deposits and that this information influences the decision making of clinicians when evaluating patients with cognitive disturbances.
Please also find here the link to a study in which the HUG is participating: https://amypad.eu
The test is the first step for the evaluation of the brain, as it can measure with millimetric precision the structure of the brain. MRI can for example measure the volume of different brain areas, the integrity of fibers connecting brain areas, the presence of alterations to the blood vessels in the brain, all changes that can indicate if there is a brain disease.